title: Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
abstract: OBJECTIVE
  We aimed to compare the preventive effect of 5-day administration of aprepitant with single administration of fosaprepitant meglumine against nausea and vomiting symptoms due to highly emetogenic chemotherapy regimens comprising cisplatin (CDDP).
  
  
  METHODS
  Subjects were inpatients who underwent chemotherapy for gastric cancer, esophageal cancer, lung cancer, or head and neck cancer with a regimen comprising 60 mg/m(2) or higher dose of CDDP. In this randomised, open-label, controlled study, the subjects were assigned to a group given aprepitant for 5 days or a group given a single administration of fosaprepitant meglumine. The nausea and vomiting symptoms that emerged within 7 days after the first CDDP administration were investigated with a questionnaire form; the results were compared between the two groups. Risk factors affecting nausea and vomiting symptoms were also investigated.
  
  
  RESULTS
  Of the 101 patients enrolled, 93 patients were included (48 in the 5-day aprepitant group and 45 in the single fosaprepitant meglumine group). No significant intergroup differences in the complete response rate or the complete control rate were found over the entire period. The nausea score tended to increase from day 3 in both groups, but no significant intergroup difference was observed. Furthermore, the investigation of risk factors affecting moderate or severe nausea symptoms indicated that the fosaprepitant meglumine administration was not a risk factor.
  
  
  CONCLUSIONS
  Single administration of fosaprepitant meglumine was not inferior to 5-day administration of aprepitant for preventing acute and delayed nausea and vomiting symptoms occurring after administration of CDDP (60 mg/m(2) or higher).
authors.affiliation: Department of Clinical Pharmacy, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Ando
authors.affiliation: Department of Clinical Pharmacy, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan. taka-h@fujita-hu.ac.jp.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Hayashi
authors.affiliation: Department of Pharmacy, Fujita Health University Hospital, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.|Department of Hematology, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Kaori
authors.initials: K
authors.lastname: Ito
authors.affiliation: Department of Pharmacy, Fujita Health University Hospital, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Eri
authors.initials: E
authors.lastname: Suzuki
authors.affiliation: Department of Pharmacy, Fujita Health University Hospital, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Mine
authors.affiliation: Department of Pharmacy, Fujita Health University Hospital, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Ayumi
authors.initials: A
authors.lastname: Miyamoto
authors.affiliation: Department of Clinical Pharmacy, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Miyuki
authors.initials: M
authors.lastname: Oya
authors.affiliation: Department of Clinical Pharmacy, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Hidezo
authors.initials: H
authors.lastname: Matsuda
authors.affiliation: Department of Clinical Pharmacy, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Ami
authors.initials: A
authors.lastname: Isaji
authors.affiliation: Department of Respiratory Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Nakanishi
authors.affiliation: Department of Respiratory Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Imaizumi
authors.affiliation: Department of Gastroenterology, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Shibata
authors.affiliation: Department of Otolaryngology, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Tatsuyoshi
authors.initials: T
authors.lastname: Okada
authors.affiliation: Department of Otolaryngology, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Sakurai
authors.affiliation: Department of Otolaryngology, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Kensei
authors.initials: K
authors.lastname: Naito
authors.affiliation: Department of Upper Gastrointestinal Surgery, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Uyama
authors.affiliation: Department of Medical Oncology, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Kawada
authors.affiliation: Division of Medical Statistics, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takahashi
authors.affiliation: Department of Clinical Pharmacy, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
authors.forename: Shigeki
authors.initials: S
authors.lastname: Yamada
mesh_terms: D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000077608:Aprepitant; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008536:Meglumine; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000188:drug therapy; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D009025:Morpholines; D000077608:Aprepitant; D008536:Meglumine; C579707:fosaprepitant; D002945:Cisplatin
keywords: Aprepitant; Chemotherapy-induced nausea and vomiting; Complete response; Fosaprepitant meglumine; Highly emetogenic chemotherapy